SignalXSignalX

ORIC Oric Pharmaceuticals, Inc.

Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Oric Pharmaceuticals, Inc. Overview

Oric Pharmaceuticals, Inc. (ORIC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Market conditions risk of banking insolvency triggered by 2023 Silicon Valley Bank receivership causing temporary funds inaccessibility
  • • Most material update: Net loss $99M for nine months ended Sept 30, 2025; accumulated deficit $661.7M, reflecting ongoing significant losses
+3 more insights

Get deeper insights on Oric Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.